If you are looking for stocks with good return, Citius Pharmaceuticals Inc can be a profitable investment option. Based on our forecasts, a long-term increase is expected, the "CTXR" stock price prognosis for 2027-01-22 is 5.596 USD. With a 5-year investment, the revenue is expected to be around +298.3%.
Is Citius Pharma a good buy?
Citius Pharmaceuticals, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of CTXR, demonstrate its potential to underperform the market. It currently has a Growth Score of B.
Why is CTXR stock down?
Shares of Citius Pharmaceuticals (NASDAQ: CTXR), a clinical-stage biopharmaceutical company, are getting beaten down today after the company released disappointing news regarding its lead candidate, Mino-Lok.
Will CTXR go up?
Will Citius Pharmaceuticals stock price grow / rise / go up? Yes. The CTXR stock price can go up from 1.405 USD to 2.217 USD in one year.
Is CTXR a good buy?
Out of 1 analysts, 1 (100%) are recommending CTXR as a Strong Buy, 0 (0%) are recommending CTXR as a Buy, 0 (0%) are recommending CTXR as a Hold, 0 (0%) are recommending CTXR as a Sell, and 0 (0%) are recommending CTXR as a Strong Sell. What is CTXR's earnings growth forecast for 2022-2024?
Is Citius Pharma a buy?
Citius Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Will Citius Pharmaceuticals stock go up?
Fair opening price Current price
----------------------------------- ------------------
$1.39 $1.41 (Overvalued)